Join us at the European Academy of Neurology (EAN) for a pivotal discussion driving the future of Alzheimer’s disease care. This session will delve into the critical journey of Alzheimer’s disease biomarkers, bridging research with clinical applications. Attendees will gain insights from leading experts and connect with professionals dedicated to transforming Alzheimer’s treatment. If you are registered to EAN, you can watch the live session online: https://ow.ly/YmyU50SqTP2 #EAN2024 | #AlzheimersResearch | #HCPs
Biogen’s Post
More Relevant Posts
-
Adriana González-Caballero joined her Kx Advisors and BGB Group colleagues reporting on findings from the annual Alzheimer's Association International Conference in Philly as one of our distinguished neurology experts. In partnership with Chris Waybill, Chloe Weiser, and BGB Group colleagues Juan M. Valdez Capuccino, Ph.D. and Exene Anderson, PhD, Adriana is digging a bit deeper into one of the topics that came up - diagnostic hurdles and blood biomarkers in Alzheimer's Disease diagnosis. Did you know the average predicted wait time between clinical diagnosis and treatment of AD is 18.6 months? We invite you to learn more about the different types of BBMs and how they may evolve patient diagnosis of AD and the treatment journey. Read more about this topic in the link below: https://go.bgbx.ai/BBBM
To view or add a comment, sign in
-
Amyloid and Tau models recapitulate pathological processes found in patients with Alzheimer’s Disease, including protein aggregation, neuroinflammation, neurodegeneration, and cognitive impairments. The key to understanding a therapeutic compound’s effect on amyloid-beta pathology-induced neuroinflammation, is to use robust and reliable models that consistently show progressive plaque pathology, such as the APP/PS1 (ARTE10) model. View example histopathological data here: https://lnkd.in/eKhpC6nX To view other models, browse through InnoSer's portfolio here: https://lnkd.in/ejQFTpA6 👉 Do you have specific questions relating to our Alzheimer's disease models? Our InnoSer neurology team is exhibiting (booth #22) at the upcoming #ADPD2024 conference and will be happy to answer any of your questions relating to Alzheimer's or other neurodegenerative disease models.
To view or add a comment, sign in
-
A paper published in Nature Reviews Neurology, discusses suspected non-AD pathophysiology (SNAP), which is common in individuals with MCI and normal cognition (NC). People with NC-SNAP have a low risk of cognitive decline over 7 years, and longer follow-up studies are needed to demonstrate whether they will eventually show faster cognitive decline than those with NC and normal biomarkers. People with MCI-SNAP have an increased risk of developing clinical AD dementia at follow-up (annual conversion rate 7% compared with 1% for MCI with normal biomarkers). This finding suggests that SNAP might partly reflect a lack of sensitivity of biomarkers to detect early amyloid pathology, although misdiagnosis at follow-up is another possibility. The frequency of AD genetic risk factors in A− T+ individuals with SNAP is similar to that in control individuals and lower than in those with AD. This finding is mainly driven by a lower frequency of APOE ε4 in SNAP than in AD. CSF proteomics have shown that people with SNAP have increased CSF levels of Aβ38 and Aβ40 compared with patients with AD and control individuals, possibly reflecting the effects of tau pathology without marked amyloid aggregation. A distinguishing feature in people with MCI-SNAP is a decrease in CSF levels of proteins that are highly expressed in the choroid plexus, suggesting a role for this structure in MCI-SNAP. Neuropathological studies have indicated a range of possible neuropathologies associated with SNAP, including TDP43-related pathologies (LATE and FTLD-TDP), tau pathology (PART, AGD and PSP), LBD and cerebrovascular pathology. In older individuals, SNAP probably represents a combination of neuropathological lesions. Nature Portfolio Springer Nature Group #neuroscience #neurology #neurologicaldisorders #neurodegenerativedisorders #alzheimersdisease #alzheimer #cognitivedecline #dementia #biomarkers #precisionmedicine #diagnosis #earlydiagnosis #earlydetection #prediction #SNAP #PART #FTD #ALS #Parkinsonsdisease #AGD #PSP #LATE #neuropathology #brain #brainresearch #clinicalresearch #MCI #cognition #amyloid #pathophysiology #riskfactors #classification #differentialdiagnosis
I’m thrilled to share our recent review and meta-analysis on the clinical importance of Suspected Non-Alzheimer disease Pathophysiology (SNAP) that is now published in Nature Reviews Neurology. SNAP is a heterogeneous biomarker-based concept that describes individuals with normal amyloid and abnormal tau and/or neurodegeneration biomarker status. In this review, we describe the origins of the SNAP construct, along with its prevalence, diagnostic and prognostic implications, and underlying neuropathology. You can read the full paper here: https://rdcu.be/dHrrE Special thanks to Aurore Delvenne Clifford Jack Dietmar Thal Pieter Jelle Visser
To view or add a comment, sign in
-
Sano CEO Patrick Short and Dr. Andrea Gropman, an expert in pediatric neurology, genetics, and inborn errors of metabolism, recently sat down for a fascinating conversation on the impact of genetics on modern medical practice. In the clip below, Dr. Gropman discusses industry areas she's keen to see improve. Feel free to check out the full webinar here: https://lnkd.in/emNSfvfY. #PrecisionMedicine #Genomics #ClinicalTrials
To view or add a comment, sign in
-
Strategic Marketing | Customer-Focused | Global Solutions | Precision Medicine | Cell & Gene Therapy | Oncology
In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/g5WfaQeQ
To view or add a comment, sign in
-
In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gnhdGAiZ
To view or add a comment, sign in
-
Drug Development/Early Development | Safety Assessment/Toxicology/DMPK/Bioanalytical/IND Enabling | Business Development
In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gRSXXdku
To view or add a comment, sign in
-
Zai Lab (NASDAQ: ZLAB, SEHK: 9688) has announced a study led by Professors Sushan Luo and Chongbo Zhao from Huashan Hospital, Fudan University, published in the Annals of Clinical and Translational Neurology. This research represents the first multi-center, real-world cohort study in China evaluating Efgartigimod for the treatment of generalized myasthenia gravis (gMG). Under an exclusive licensing agreement with argenx, Zai Lab is developing and commercializing Efgartigimod in Greater China to address significant unmet needs in autoimmune conditions. Key findings from the study include: - 97% of patients experienced clinically meaningful improvement within an average of 1.3±0.7 weeks. - Efgartigimod demonstrated efficacy across various antibody types and disease states, including MuSK antibody-positive, seronegative, acute exacerbation, and myasthenic crisis patients. - Approximately 70% of patients transitioned to a mild disease state, and 39% achieved minimal symptom expression after 12 weeks of follow-up. - The average daily dose of corticosteroids decreased from 28.3mg at baseline to 15.7mg over 12 weeks. #HealthcareInnovation #RareDiseases #ClinicalResearch #AutoimmuneDiseases #Neurology #Efgartigimod #QimingPortfolio #QimingHealthcare
To view or add a comment, sign in
-
Generalized myasthenia gravis is a chronic autoimmune disorder without a cure. A recent study by Zai Lab showed favorable results with Efgartigimod. Approximately 70% of patients transitioned to a mild disease state, with 39% achieving minimal symptom expression. These improvements are significant for patients and caregivers alike. #Qiming #QimingPortfolio #healthcare #ZaiLab #Clinical #TranslationalNerology #Efgartigimod #gMg #MyastheniaGravis #Argenx #medtech #biotech #Antibody
Zai Lab (NASDAQ: ZLAB, SEHK: 9688) has announced a study led by Professors Sushan Luo and Chongbo Zhao from Huashan Hospital, Fudan University, published in the Annals of Clinical and Translational Neurology. This research represents the first multi-center, real-world cohort study in China evaluating Efgartigimod for the treatment of generalized myasthenia gravis (gMG). Under an exclusive licensing agreement with argenx, Zai Lab is developing and commercializing Efgartigimod in Greater China to address significant unmet needs in autoimmune conditions. Key findings from the study include: - 97% of patients experienced clinically meaningful improvement within an average of 1.3±0.7 weeks. - Efgartigimod demonstrated efficacy across various antibody types and disease states, including MuSK antibody-positive, seronegative, acute exacerbation, and myasthenic crisis patients. - Approximately 70% of patients transitioned to a mild disease state, and 39% achieved minimal symptom expression after 12 weeks of follow-up. - The average daily dose of corticosteroids decreased from 28.3mg at baseline to 15.7mg over 12 weeks. #HealthcareInnovation #RareDiseases #ClinicalResearch #AutoimmuneDiseases #Neurology #Efgartigimod #QimingPortfolio #QimingHealthcare
To view or add a comment, sign in
-
In a recent conversation with Robert Martone, scientific discipline director for neurology, we discussed the acceleration and expansion of biomarkers in therapeutic development for neurodegenerative diseases such as Alzheimer’s, Parkinson’s, dementia and more. Read the full Q&A: https://lnkd.in/gc_S7eiv
To view or add a comment, sign in
1,034,501 followers